St. Jude Children’s Research Hospital scientists found that despite having few mutations, pediatric acute lymphoblastic leukemia does not escape immune detection
(MEMPHIS, Tenn.–JUNE 26, 2019) St. Jude Children’s Research Hospital scientists have evidence that children with acute lymphoblastic leukemia mount a robust immune response to their cancer. The findings, which appear today in the journal Science Translational Medicine, will likely aid development of immunotherapy for the most common childhood cancer.
Immunotherapy has revolutionized cancer treatment in the last decade, particularly for adults with melanoma, lung cancer and other solid tumors. But immunotherapies for pediatric cancer have lagged. Some immunotherapeutics, including immune checkpoint inhibitors, have worked best against high-mutation tumors and proved less effective against most pediatric cancer, which involve fewer mutations. Researchers speculated that the immune system fails to recognize or respond to tumors with fewer mutations, including pediatric ALL.
“The results of this study flip that story on its head,” said corresponding author Paul Thomas, Ph.D., a member of the St. Jude Department of Immunology. “Using a variety of methods, we demonstrated that the tumor mutational burden does not necessarily determine the ability of tumor cells to be recognized by T cells or to elicit an immune response.
“The findings suggest that the immune system could be used to effectively target pediatric ALL,” he said. While more than 90 percent of children with ALL in the U.S. become long-term survivors, the outlook remains bleak for patients who relapse.
Searching for an immune response
For this study, Thomas and his colleagues took a closer look at the immune response in children with pediatric ALL. The scientists checked for specialized anti-tumor T cells (CD8+ T cells) that recognize patient-specific mutant proteins. The recognition launches the immune response that kills tumor cells.
Researchers found anti-tumor T cells that recognized 86% of the pediatric ALL mutations and specifically targeted 68% of the leukemic cells. That percentage is far greater than the 2% of solid tumor mutations that anti-tumor T cells are predicted to target.
“Given that we were able to identify tumor-reactive T cells that were functional suggests traditional immune checkpoint inhibitors may not be the best option for these patients,” said first author Anthony Zamora, Ph.D., a postdoctoral fellow in Thomas’ laboratory. “Cellular-based approaches that allow patients’ T cells to be modified to increase the specificity and magnitude of the anti-tumor response could show greater clinical efficacy.”
Immunodominance
Thomas and his colleagues made an analogy between viral and tumor immune responses as a possible explanation for the high levels of immune recognition in this study. Large viruses, like high-mutation tumors, produce many possible immune targets. During viral infections, a process called immunodominance leads to a focused immune response that includes production of T cells against a limited number of viral targets.
“The same process may be at work in tumors like pediatric ALL that have fewer mutations,” Thomas said. “As a result, the immune system might end up targeting a greater percentage of leukemic mutations, including driver mutations that are responsible for the cancer.”
###
The other authors are Jeremy Chase Crawford, E. Kaitlynn Allen, Xi-zhi Guo, Robert Carter, Hossam Abdelsamed, Ardiana Moustaki, Yongjin Li, Ti-Cheng Chang, Walid Awad, Charles Mullighan, James R. Downing, Terrence Geiger, Taosheng Chen, Douglas Green, Benjamin Youngblood and Jinghui Zhang, of St. Jude; and Jesse Bakke and Mari Dallas, formerly of St. Jude.
The research was funded in part by grants (AI107625, AI136514, GM118041, CA197695-01A1, GM11527902, CA09683212, AI11442) from the National Institutes of Health; Key for a Cure Foundation; and ALSAC, the fundraising and awareness organization of St. Jude.
St. Jude Media Relations Contacts
Marvin Stockwell
Desk: 901-595- 6384
Cell: 901-734-8766
[email protected]
[email protected]
Michael Sheffield
Desk: (901) 595-0221
Cell: (901) 379-6072
[email protected]
[email protected]
St. Jude Children’s Research Hospital
St. Jude Children’s Research Hospital is leading the way the world understands, treats and cures childhood cancer and other life-threatening diseases. It is the only National Cancer Institute-designated Comprehensive Cancer Center devoted solely to children. Treatments developed at St. Jude have helped push the overall childhood cancer survival rate from 20 percent to 80 percent since the hospital opened more than 50 years ago. St. Jude freely shares the breakthroughs it makes, and every child saved at St. Jude means doctors and scientists worldwide can use that knowledge to save thousands more children. Families never receive a bill from St. Jude for treatment, travel, housing and food — because all a family should worry about is helping their child live. To learn more, visit stjude.org or follow St. Jude on social media at @stjuderesearch.
Media Contact
Michael Sheffield
[email protected]
